10/5/2015. Hypertension GuidelinesDate JNC JNC 72003 JNC 82013 NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.

Slides:



Advertisements
Similar presentations
JNC 8 Guidelines….
Advertisements

ASCOT ASCOT STUDY. ASCOT INTRODUCTION AND AIMS EXISTING KNOWLEDGE BACKGROUND OF ASCOT STUDY DESIGN (TWO ARMS (BPLA,LLA) METHODOLOGY TREATMENT REGIMES.
Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
1 Excess Dietary Sodium: Impact on Hypertension and Health Outcomes Presenters name Institution Updated April 2011.
CKD In Primary Care Dr Mohammed Javid.
CVD risk estimation and prevention: An overview of SIGN 97.
Etiology Primary hypertension 95% of all cases Secondary hypertension – 5% of all cases – Chronic renal disease – most common White coat hypertension –
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Pharmacological Treatment of Hypertension Update 2012.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
HOME AND AMBULATORY BLOOD PRESSURE MONITORING
Systemic Hypertension. Systemic blood pressure measures 140/90 mm Hg or higher on at least two occasions a minimum of 1 to 2 weeks apart.
DR. IDOWU AKOLADE EDM DIVISION LUTH
0CTOBER 2010 An Approach for Sub-Saharan Africa. Dr. Linda Hawker, MD, CCFP General Practice Kelowna BC Canada.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
Blood pressure control in primary health care WORKSHOP
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Hypertension Dr Nidhi Bhargava 8/10/13. Why Treat Increased risk of cardiovascular death and mortality Increased systolic, diastolic and pulse pressures.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
PHARMACOTHERAPY OF HYPERTENSION Based on New Guidelines Fariborz Nikaeen; MD Interventional cardiologist 2 november 2015.
A Controlled Trial of Renal Denervation for Resistant Hypertension
SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
Antonio Coca, MD, PhD, FRCP, FESC
Management of Hypertension according to JNC 7
Hypertension In The Stroke Patient
Nephrology Journal Club The SPRINT Trial Parker Gregg
David Antecol, M.D., FACC, FASH, FRCP(C) Specialist in Clinical Hypertension (American Society of Hypertension) Disclosures: None.
Hypertension guidelines What’s all the controversy about 2015
JNC VIII Hypertension.
Hypertension JNC VIII Guidelines.
FDA Pathway to Approval: Clinical Requirements for Renal Denervation
Judith H. Veis, MD, FACP Associate Director, Nephrology
Jan B. Pietzsch1, Benjamin P. Geisler1, Murray D. Esler 2
What’s New in the 2013 ESC/ESH Hypertension Guideline
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
The Anglo Scandinavian Cardiac Outcomes Trial
Achieving the Clinical Potential of RAAS Blockade
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Systolic Blood Pressure Intervention Trial (SPRINT)
Managing Complex Hypertension: What Every Physician Should Know
Section VIII. Ambulatory BP Measurement
Managing Hard-To-Treat Hypertension: What Every Physician Should Know
Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Section III: Neurohormonal strategies in heart failure
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Controlling Elevated Blood Pressure
Primary Hypertension Max C. Reif, M.D.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Internal Medicine Workshop Series Laos September /October 2009
Presentation transcript:

10/5/2015

Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007 Reappraisal of 2007 Hypertension Guidelines September 2009

10/5/2015  The JNC 8 guidelines released towards the end of 2013, had several new things to offer  One highly discussed recommendation was that for patients aged 60 or above who don’t have DM and CKD, the target BP of 150/90 (instead of 140/90)…  The American society of hypertension and the European society for hypertension have stuck to the previous guidelines of 140/90.While BP of 150/90 may be acceptable, there is a consensus on evidence that with a target of 140/90 we are more sure about the reduction in risk of CVD and  For patients between 18 to 59 years and those who not have DM and CKD,the target BP is 140/90.

10/5/ Not evidence based recommendation 2. Recommendations by expert opinion only 3.Not unanimous, 5 members of the panel have disagreed 4.All societies have not accepted those recommendations 5.Some what controversial

10/5/2015

SYMPLICITY HTN-3 SYMPLICITY HTN-4 RandomizedYes ControlledYes BlindedYes Number of subjectsMore than 500 Number of Centers Participating Up to 90 in the USUp to 100 in the US Blood Pressure Required for Inclusion > 160 mmHg Systolic mmHg Systolic

10/5/2015

1. Hypertension is the commonest clinical disorder and is a major health problem worldwide. 2. Inadequately controlled or uncontrolled hypertension leads to subclinical organ damage which can be progressive, leading to serious cardiovascular events like angina, MI and CHF, TIA and stroke, chronic renal failure, peripheral vascular disease and retinopathy. 3. Optimization of drug therapy with 1, 2 or 3 anti hypertensive agents in combination and /or full doses may be necessary.

4. Ambulatory and home B.P. monitoring should be encouraged 5. JNC 8 defined new target goals and has advised first line drugs and later line therapy. 6. Renal denervation therapy initially showed significant promise but in randomized blind trials with sham procedures, there was no significant difference in the B.P. levels upto 6 month in RDT vs control patients.

7. Some reports suggest benefit in uncontrolled hypertension with chronic renal failure. 8. Life style modification, reduced salt intake prevention of diabetes and obesity, cessation of smoking and use of appropriately tailored drug therapy can prevent end organ catastrophies.